HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb
HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb
复制标题
DOI：
10.1007/s10156-005-0385-z
复制
发表时间：
2005-08-01
影响因子：
2.2
通讯作者：
Aiello, Pasquale
中科院分区：
文献类型：
--
作者：
Sarrecchia, Cesare;Cappelli, Alessandra;Aiello, Pasquale
1例51岁男性，乙肝表面抗原(HBs)阴性，抗乙肝表面抗原(抗-HBs)和抗乙肝核心抗原(抗-HBc)阳性，在利妥昔单抗治疗慢性淋巴细胞白血病的过程中，发生乙肝病毒感染的再激活，合并肝炎，尽管接受拉米夫定治疗，但仍进展为肝功能衰竭和死亡。尽管HBVDNA滴度很高，但HBs Ag仍持续阴性。我们观察到，在接受利妥昔单抗治疗的患者中，其他致命的乙肝病毒感染重新激活的病例表明，在所有以前有乙肝病毒感染标志物的患者中，在利妥昔单抗治疗期间应该考虑拉米夫定的预防。
A 51-year-old man who was hepatitis B surface antigen (HBsAg)-negative and positive for anti-hepatitis B surface antigen (anti-HBs) and anti-hepatitis B core antigen (anti-HBc), during rituximab therapy for chronic Lymphocytic leukemia, developed reactivation of hepatitis B virus (HBV) infection with hepatitis that proceeded towards hepatic failure and death in spite of lamivudine therapy. HBsAg remained persistently negative, notwithstanding a high HBV-DNA titer. Our observation, following other cases of fatal reactivation of HBV infection in patients receiving rituximab, suggests that, in all patients with previous markers of HBV infection, lamivudine prophylaxis should be considered during rituximab therapy.